Evidence map›Paper›PMID 42908606›Full record

ArticleFrontiers in endocrinology2026

Liraglutide reduces lipid accumulation in human orbital fibroblasts in Graves' orbitopathy.

Chih-Wei Shih, Shyang-Rong Shih, Yi-Hsuan Wei, Chia-Hung Lin, Shu-Lang Liao, Ting-An Chou, I Chu, Hou-Jen Chen, Neng-Li Liao, Feng-Chiao Tsai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chih-Wei ShihGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Shyang-Rong ShihDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yi-Hsuan WeiDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Hung LinDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shu-Lang LiaoDepartment of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.
Ting-An ChouDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
I ChuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hou-Jen ChenDepartment of Pharmacology, National Taiwan University College of Medicine, Taipei, Taiwan.
Neng-Li LiaoDepartment of Pharmacology, National Taiwan University College of Medicine, Taipei, Taiwan.
Feng-Chiao TsaiDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graves' orbitopathy (GO) is characterized by proliferation and differentiation of orbital fibroblasts. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for metabolic disorders and have been reported to modulate cell proliferation and differentiation. The present study aimed to examine the effects of GLP-1RAs on key fibroblast-mediated pathogenic processes relevant to GO using human orbital fibroblasts. Orbital fibroblasts were isolated from patients with GO and non-GO controls. Cells were treated with the GLP-1RAs liraglutide (100 nM) or semaglutide (200 nM). Fibroblast proliferation was assessed by nuclear counting, lipid accumulation was evaluated by Oil Red O staining of oil droplets, and myofibroblastic differentiation was assessed by α-smooth muscle actin (α-SMA) immunostaining. Hyaluronan production was measured by ELISA.

Indexed as

FibroblastsGraves OphthalmopathyLipid MetabolismLiraglutideOrbitAdultCell DifferentiationCell ProliferationCells, CulturedFemaleGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHumansMaleMiddle AgedSemaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesLiraglutideSemaglutideglucagon-like peptide-1 receptor agonistsGraves’ orbitopathylipid accumulationorbital fibroblaststhyroid eye disease

Identifiers

PMID42908606
PMCPMC13682971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.